Skip to main content

Table 2 FeNO change from baseline ratio following onset and cessation of treatment

From: Anti-inflammatory duration of action of fluticasone furoate/vilanterol trifenatate in asthma: a cross-over randomised controlled trial

A: FeNO change from baseline and FF/VI:placebo ratio following onset of treatment
Day of treatment Time point Geometric LSmean Ratio (FF/VI vs Placebo) 95% CI of the Ratio
n FF/VI 100/25 mcg n Placebo   
1 PM 25 0.97 26 0.90 1.09 (0.91,1.29)
2 AM 27 0.91 27 1.00 0.91 (0.77,1.07)
  PM 27 0.81 25 0.89 0.91 (0.77,1.08)
3 AM 27 0.75 27 0.95 0.79 (0.67,0.94)
  PM 27 0.64 25 0.88 0.72 (0.61,0.86)
4 AM 26 0.52 27 0.90 0.58 (0.49,0.69)
  PM 27 0.48 27 0.89 0.54 (0.46,0.64)
5 AM 27 0.46 27 0.99 0.47 (0.39,0.55)
  PM 26 0.45 26 0.95 0.47 (0.40,0.56)
6 AM 26 0.45 27 0.97 0.46 (0.39,0.55)
  PM 27 0.41 27 0.96 0.42 (0.36,0.50)
7 AM 27 0.45 26 0.96 0.47 (0.39,0.56)
  PM 27 0.39 27 0.88 0.45 (0.38,0.53)
8 AM 27 0.40 27 0.94 0.43 (0.37,0.51)
  PM 27 0.37 26 0.90 0.41 (0.34,0.48)
9 AM 26 0.39 27 0.99 0.40 (0.33,0.47)
  PM 25 0.34 25 0.89 0.38 (0.32,0.46)
10 AM 26 0.36 26 0.93 0.39 (0.33,0.46)
  PM 27 0.36 26 0.90 0.40 (0.34,0.47)
11 AM 27 0.33 27 0.92 0.36 (0.30,0.42)
  PM 27 0.31 27 0.88 0.36 (0.30,0.42)
12 AM 27 0.39 27 0.94 0.42 (0.35,0.49)
  PM 27 0.35 27 0.91 0.39 (0.33,0.46)
13 AM 24 0.34 25 0.99 0.35 (0.29,0.41)
  PM 24 0.32 25 0.94 0.34 (0.29,0.40)
14 AM 23 0.38 23 1.00 0.37 (0.32,0.44)
  PM 23 0.32 22 1.00 0.32 (0.27,0.37)
B: FeNO change from baseline and FF/VI:placebo ratio following cessation of treatment
Day relative to last dose Time point Geometric LSmean Ratio (FF/VI vs Placebo) 95% CI of the Ratio
   n FF/VI 100/25 mcg n Placebo   
1 AM 27 0.38 27 1.03 0.36 (0.31,0.43)
  PM 27 0.32 27 0.98 0.33 (0.28, 0.39)
2 AM 27 0.38 27 0.99 0.38 (0.32, 0.45)
  PM 27 0.35 27 0.94 0.37 (0.31, 0.44)
3 AM 27 0.45 27 0.98 0.46 (0.39, 0.54)
  PM 27 0.42 27 0.91 0.47 (0.40, 0.56)
4 AM 27 0.55 27 0.98 0.56 (0.47, 0.66)
  PM 27 0.49 27 0.85 0.58 (0.49, 0.69)
5 AM 27 0.52 27 0.83 0.63 (0.53, 0.75)
  PM 26 0.48 26 0.72 0.67 (0.57, 0.80)
6 AM 26 0.53 26 0.79 0.67 (0.56, 0.80)
  PM 26 0.48 24 0.78 0.62 (0.52, 0.74)
7 AM 27 0.49 27 0.82 0.60 (0.51, 0.71)
  PM 25 0.49 25 0.79 0.62 (0.52, 0.74)
8 AM 27 0.56 25 0.82 0.69 (0.58, 0.81)
  PM 26 0.56 27 0.82 0.68 (0.57, 0.80)
9 AM 27 0.61 27 0.92 0.66 (0.56, 0.78)
  PM 27 0.62 27 0.91 0.68 (0.57, 0.80)
10 AM 26 0.66 24 1.01 0.66 (0.55, 0.78)
  PM 27 0.67 27 0.98 0.68 (0.58, 0.81)
11 AM 26 0.77 26 1.06 0.73 (0.61, 0.86)
  PM 27 0.74 27 1.01 0.73 (0.61, 0.86)
12 AM 27 0.73 27 1.01 0.72 (0.61, 0.85)
  PM 27 0.70 27 0.99 0.71 (0.60, 0.84)
13 AM 25 0.76 27 1.05 0.72 (0.61, 0.86)
  PM 25 0.74 25 0.95 0.78 (0.66, 0.93)
14 AM 27 0.79 26 1.00 0.79 (0.66, 0.93)
  PM 26 0.63 25 0.95 0.67 (0.56, 0.79)
15 AM 26 0.76 26 0.97 0.79 (0.66, 0.93)
  PM 25 0.73 25 0.92 0.79 (0.66, 0.94)
16 AM 27 0.75 26 1.01 0.74 (0.62, 0.87)
  PM 27 0.73 26 1.01 0.73 (0.61, 0.86)
17 AM 26 0.79 25 1.03 0.77 (0.65, 0.91)
  PM 16 0.79 18 0.97 0.81 (0.65, 1.01)
18 AM 14 0.75 17 0.98 0.77 (0.61, 0.96)
  PM 10 0.67 14 0.87 0.77 (0.59, 1.00)
19 AM 10 0.78 14 0.96 0.81 (0.63, 1.05)
  PM 6 0.67 12 0.93 0.72 (0.52, 1.00)
20 AM 6 0.77 12 0.99 0.78 (0.56, 1.09)
  PM 5 0.72 7 0.92 0.78 (0.53, 1.14)
21 AM 6 0.85 7 1.00 0.85 (0.59, 1.22)
  PM 5 0.75 7 0.99 0.75 (0.50, 1.13)
  1. Legend: Summary of repeated measures statistical analysis of ratio from baseline exhaled nitric oxide (ppb) data after A) onset and B) cessation of repeat dose of treatment. Decrease in n value is seen from Day 17 after last dose due to permitted study visit windows